Canadian Manufacturing

Russia turns to China for vaccine manufacturing help

In spite of the delays, Russia's vaccine diplomacy has made gains.

May 3, 2021  by Associated Press

Russia is turning to multiple Chinese firms to manufacture the Sputnik V coronavirus vaccine in an effort to speed up production as demand soars for its shot.

Russia has announced three deals totalling 260 million doses with Chinese vaccine companies in recent weeks. It’s a decision that could mean quicker access to a shot for countries in Latin America, the Middle East, and Africa that have ordered Russia’s vaccine, as the U.S. and the European Union focus mainly on domestic vaccination needs.

Earlier criticism about Russia’s vaccine have been largely quieted by data published in the British medical journal The Lancet that said large-scale testing showed it to be safe, with an efficacy rate of 91%.

Yet, experts have questioned whether Russia can fulfil its pledge to countries across the world. While pledging hundreds of millions of doses, it has only delivered a fraction.

Advertisement

Kremlin spokesman Dmitry Peskov has said demand for Sputnik V significantly exceeds Russia’s domestic production capacity.

To boost production, the Russian Direct Investment Fund, which bankrolled Sputnik V, has signed agreements with multiple drug makers in other countries, such as India, South Korea, Brazil, Serbia, Turkey, Italy and others. There are few indications, however, that manufacturers abroad, except for those in Belarus and Kazakhstan, have made any large amounts of the vaccine so far.

Airfinity, a London-based science analytics company, estimates Russia agreed to supply some 630 million doses of Sputnik V to over 100 countries, with only 11.5 million doses exported so far.

The Russian Direct Investment Fund, which has been in charge of international co-operation for Sputnik V, said in April it would produce 100 million doses in collaboration with Hualan Biological Bacterin Inc., in addition to an earlier deal announced in March for 60 million doses with Shenzhen Yuanxin Gene tech Co.

However, none of the three Chinese companies have yet to start manufacturing Sputnik V.

The timeline for the newest deals are also unclear. Hualan Bio was among the 10 largest vaccines manufacturers in China in 2019. Phone calls to Hualan Bio went unanswered.

In spite of the delays, Russia’s vaccine diplomacy has made gains.

“Russia has been able to build stronger diplomatic ties and in areas where it hasn’t been able to,” before, said Imogen Page-Jarrett, an analyst at EIU. “They have this window of opportunity while the US, E.U. and India are focusing on domestic and the rest of the world is crying out for a vaccine supply.”